Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway
Authors:
Open Access
- 1 May 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 4359-4377
Abstract
Background: Deferoxamine (DFO) is a commonly used iron chelator, which can reduce the iron levels in cells. DFO is normally used to treat iron-overload disease, including some types of cancer. However, our previous studies revealed that DFO treatment significantly increased the iron concentrations in triple-negative breast cancer cells (TNBCs) resulting in enhanced cell migration. But the mechanism of DFO-induced increasing iron uptake in aggressive TNBCs still remained unclear. Materials and methods: Iron metabolism-related proteins in aggressive breast cancer MDA-MB-231, HS578T and BT549 cells and nonaggressive breast cancer MCF-7 and T47D cells were examined by immunofluorescence and Western blotting. The possible regulatory mechanism was explored by Western blotting, co-incubation with neutralizing antibodies or inhibitors, and transwell assay. Results: In this study, we found that DFO treatment significantly increased the levels of iron uptake proteins, DMT1 and TfR1, in aggressive TNBCs. Moreover, both TfR1 and DMT1 expressed on cell membrane were involved in high iron uptake in TNBCs under DFO-induced iron deficient condition. For the possible regulatory mechanism, we found that DFO treatment could promote a high expression level of IL-6 in aggressive MDA-MB-231 cells. The activated IL-6/PI3K/AKT pathway upregulated the expression of iron-uptake related proteins, TfR1 and DMT1, leading to increased iron uptakes. Conclusion: We demonstrated that DFO could upregulate expression of TfR1 and DMT1 , which enhanced iron uptake via activating IL-6/PI3K/AKT signaling pathway in aggressive TNBCs.Keywords
This publication has 42 references indexed in Scilit:
- Iron participated in breast cancer chemoresistance by reinforcing IL-6 paracrine loopBiochemical and Biophysical Research Communications, 2016
- Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in diseaseBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2015
- A Probable Risk Factor of Female Breast Cancer: Study on Benign and Malignant Breast Tissue SamplesBiological Trace Element Research, 2013
- Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neuronsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Role of ferritin alterations in human breast cancer cellsBreast Cancer Research and Treatment, 2010
- Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifenBreast Cancer Research and Treatment, 2009
- Does excess iron play a role in breast carcinogenesis? an unresolved hypothesisCancer Causes & Control, 2007
- Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteinsMolecular and Cellular Biochemistry, 2007
- Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell linesThe Prostate, 2000
- Iron enhances tumor growth. Observation on spontaneous mammary tumors in miceCancer, 1991